| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Insight Molecular Diagnostics Inc.
13D/A
IMDX · 68235C206
|
39.7% |
4/27/2026
Event 4/23/2026
|
||||
| Broadwood Partners, L.P. | 39.7% | |||||
| Broadwood Capital, Inc. | 39.7% | |||||
| Neal C. Bradsher | 39.7% | |||||
|
STAAR Surgical Company
13D/A
STAA · 852312305
|
32.6% |
3/13/2026
Event 3/13/2026
|
||||
| Broadwood Partners, L.P. | 32.6% | |||||
| Broadwood Capital, Inc. | 32.6% | |||||
| Neal C. Bradsher | 32.6% | |||||
| Richard T. LeBuhn | 0% | |||||
|
Lineage Cell Therapeutics, Inc.
13D/A
LCTX · 53566P109
|
23.1% |
11/14/2025
Event 11/12/2025
|
||||
| Broadwood Partners, L.P. | 23.0% | |||||
| Broadwood Capital, Inc. | 23.0% | |||||
| Neal C. Bradsher | 23.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.